NCT02970929: A reported trial by Otsuka Pharmaceutical Development & Commercialization, Inc.
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02970929 |
|---|---|
| Title | A 26-Week Open-label Safety and Tolerability Extension Study of SEP-363856 in Adult Subjects With Schizophrenia |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 31, 2017 |
| Completion date | Jan. 29, 2019 |
| Required reporting date | Jan. 29, 2022, midnight |
| Actual reporting date | Nov. 30, 2021 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |